Sutro Biopharma’s (STRO) Outperform Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO) in a report issued on Tuesday morning,RTT News reports. Wedbush currently has a $8.00 target price on the stock.

Several other analysts have also issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research report on Monday, November 18th. Truist Financial cut their price target on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Sutro Biopharma has an average rating of “Buy” and an average price target of $12.14.

Sutro Biopharma Stock Performance

STRO stock opened at $2.35 on Tuesday. The company has a market cap of $193.78 million, a price-to-earnings ratio of -1.46 and a beta of 1.09. The business’s 50-day moving average is $3.33 and its two-hundred day moving average is $3.65. Sutro Biopharma has a fifty-two week low of $2.32 and a fifty-two week high of $6.13.

Institutional Trading of Sutro Biopharma

Several institutional investors have recently made changes to their positions in STRO. Vanguard Group Inc. boosted its stake in Sutro Biopharma by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock worth $17,079,000 after purchasing an additional 132,790 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Sutro Biopharma by 24.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after acquiring an additional 3,578 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Sutro Biopharma by 47.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 272,719 shares of the company’s stock valued at $799,000 after acquiring an additional 88,034 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in Sutro Biopharma by 15.6% in the 2nd quarter. Panagora Asset Management Inc. now owns 907,503 shares of the company’s stock worth $2,659,000 after purchasing an additional 122,299 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Sutro Biopharma by 23.3% during the 2nd quarter. Rhumbline Advisers now owns 116,099 shares of the company’s stock valued at $340,000 after purchasing an additional 21,935 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.